cilofungin: a cyclic hexapeptide echinocandin; a modified form of Echinocandin B; antimycotic agent against Candida albicans [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
cilofungin : A cyclic hexapeptide echinocandin antibiotic isolated from Aspergillus spp. By inhibiting the conversion of lanosterol to ergosterol, it invades a fungus' ability to synthesize cell walls. A modified form of echinocandin B, it is an antimycotic agent against Candida albicans. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 6918120 |
| CHEMBL ID | 2103748 |
| CHEBI ID | 315019 |
| SCHEMBL ID | 16557358 |
| MeSH ID | M0124540 |
| Synonym |
|---|
| l-646991 |
| cilofungin [usan:inn] |
| echinocandin b, 1-((4r,5r)-4,5-dihydroxy-n2-(4-(octyloxy)benzoyl)-l-ornithine)- |
| cilofungina [inn-spanish] |
| antibiotic ly 121019 |
| echinocandin b, 1-((4r,5r)-4,5-dihydroxy-n(sup 2)-(4-(octyloxy)benzoyl)-l-ornithine)- |
| cilofunginum [inn-latin] |
| 1-((4r,5r)-4,5-dihydroxy-n(sup 2)-(p-(octyloxy)benzoyl)-l-ornithine)echinocandin b |
| (4r,5r)-4,5-dihydroxy-n(sup 2)-(p-(octyloxy)benzoyl)-l-ornithyl-l-threonyl-trans-4-hydroxy-l-prolyl-(s)-4-hydroxy-4-(p-hydroxyphenyl)-l-threonyl-l-threonyl-(3s,4s)-3-hydroxy-4-methyl-l-proline cyclic (6->1)-peptide |
| (4r,5r)-4,5-dihydroxy-n(sup 2)-(p-(octyloxy)benzoyl)-l-ornithyl-l-threonyl-trans-4-hydroxy-l-prolyl-(s)-4-hydroxy-4-(p-hydroxyphenyl)-l-threonyl-l-threonyl-(3s,4s)-3-hydroxy-4-methyl-l-proline cyclic (6-1)-peptide |
| cilofungin |
| ly-121019 |
| 5.1:6-anhydro{(4r,5r)-4,5-dihydroxy-n(2)-[4-(octyloxy)benzoyl]-l-ornithyl-l-threonyl-(4r)-4-hydroxy-l-prolyl-(4s)-4-hydroxy-4-(4-hydroxyphenyl)-l-threonyl-l-threonyl-(3s,4s)-3-hydroxy-4-methyl-l-proline} |
| cilofunginum |
| ly121019 |
| cilofungina |
| n-{(2r,6s,9s,11r,12r,14as,15s,16s,20s,23s,25as)-23-[(1s,2s)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-2,11,12,15-tetrahydroxy-6,20-bis[(1r)-1-hydroxyethyl]-16-methyl-5,8,14,19,22,25-hexaoxotetracosahydro-1h-dipyrrolo[2,1-c:2',1'-l][1,4,7,10,13,16]hexaazacyc |
| cilofungine |
| CHEBI:315019 , |
| unii-8zjc54a39x |
| 8zjc54a39x , |
| CHEMBL2103748 |
| 1-((4r,5r)-4,5-dihydroxy-n2-(p-(octyloxy)benzoyl)-l-ornithine)echinocandin b |
| l-proline, (4r,5r)-4,5-dihydroxy-n2-(4-(octyloxy)benzoyl)-l-ornithyl-l-threonyl-trans-4-hydroxy-l-prolyl-(s)-4-hydroxy-4-(4-hydroxyphenyl)-l-threonyl-l-threonyl-3-hydroxy-4-methyl-, cyclic (6->1)-peptide, (2.alpha.,3.beta.,4.beta.)- |
| (4r,5r)-4,5-dihydroxy-n2-(p-(octyloxy)benzoyl)-l-ornithyl-l-threonyl-trans-4-hydroxy-l-prolyl-(s)-4-hydroxy-4-(p-hydroxyphenyl)-l-threonyl-l-threonyl-(3s,4s)-3-hydroxy-4-methyl-l-proline cyclic (6->1)-peptide |
| cilofungin [inn] |
| cilofungin [usan] |
| cilofungin [mart.] |
| antibiotic ly-121019 |
| SCHEMBL16557358 |
| n-[(3s,6s,9s,11r,15s,18s,20r,21r,24s,25s,26s)-6-[(1s,2s)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,21,25-tetrahydroxy-3,15-bis[(1r)-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-18-yl]-4-octoxyb |
| Q908879 |
| DTXSID901027438 |
Cilofungin (LY 121019) is an antifungal cyclopeptide which inhibits cell wall (1,3)-beta-glucan biosynthesis in fungal organisms. Its action against Candida albicans has been widely studied. Cilof ungin is a potentially safe antif fungus for the treatment of candida endophthalmitis.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Cilofungin treatment reduced yeast counts, especially in the kidney, with activity comparable to that of amphotericin B." | ( Treatment of experimental disseminated candidiasis with cilofungin. Durack, DT; Hobbs, MM; Perfect, JR; Wright, KA, 1989) | 1.24 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Cilofungin is a potentially safe antifungal for the treatment of candida endophthalmitis." | ( Retinal toxicity and in vitro efficacy study of cilofungin (LY121019). Niesman, MR; Peyman, GA; Shahsavari, M, 1990) | 1.44 |
Cilofungin was combined with amphotericin B or flucytosine to determine if synergistic inhibition or killing occurred against 50 strains of various Candida species.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Cilofungin, a lipopeptide antifungal agent, was tested for in vitro activity alone and in combination with ketoconazole, itraconazole, flucytosine and amphotericin B against 102 clinical isolates of Candida species." | ( In vitro comparison of cilofungin alone and in combination with other antifungal agents against clinical isolates of Candida species. Cobbs, CG; Dismukes, WE; Lank, KM; Smith, KR, 1991) | 2.03 |
| "Cilofungin was combined with amphotericin B or flucytosine to determine if synergistic inhibition or killing occurred against 50 strains of various Candida species." | ( The effect of cilofungin (LY 121019) in combination with amphotericin B or flucytosine against Candida species. Bradley, SF; Bulo, AN; Kauffman, CA, 1989) | 2.08 |
| "Cilofungin was combined with amphotericin B or flucytosine to determine if synergistic inhibition or killing occurred against 50 strains of various Candida species." | ( The effect of cilofungin (LY 121019) in combination with amphotericin B or flucytosine against Candida species. Bradley, SF; Bulo, AN; Kauffman, CA, 1989) | 2.08 |
Cilofungin has potent in vitro activity against Candida albicans, but previous in vivo models using twice daily intermittent dosing regimens have not consistently demonstrated in vivo efficacy. Dose-response experiments with this inhibitor showed that the solubilized enzyme was maximally inhibited at a cilof ungin concentration of 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cilofungin has potent in vitro activity against Candida albicans, but previous in vivo models using twice daily intermittent dosing regimens have not consistently demonstrated in vivo efficacy." | ( Efficacy of cilofungin therapy administered by continuous intravenous infusion for experimental disseminated candidiasis in rabbits. Henry, NK; Rouse, MS; Steckelberg, JM; Tallan, BM; Wilson, WR, 1992) | 2.11 |
| " Six groups of rabbits were studied, untreated controls (n = 32) and five cilofungin dosage regimen groups consisting of the following: 25 mg/kg of body weight intravenously twice daily (VLoINT) (n = 9); 50 mg/kg twice daily (LoINT) (n = 9); 90 mg/kg twice daily (HiINT) (n = 11); 5 mg/kg/h for 18 h/day (LoCI) (n = 7); and 10 mg/kg/h for 18 h/day (HiCI) (n = 7)." | ( Antifungal effects of the nonlinear pharmacokinetics of cilofungin, a 1,3-beta-glucan synthetase inhibitor, during continuous and intermittent intravenous infusions in treatment of experimental disseminated candidiasis. Bacher, J; Coleman, D; Gordee, R; Kelly, P; Lecciones, J; Lee, JW; Lyman, C; Pizzo, PA; Thomas, V; Walsh, TJ, 1991) | 0.76 |
| " The in vitro activity of LY121019 is marked by a paradoxical dose-response with isolates of Candida albicans and Candida tropicalis and is influenced by choice of inoculum size, time and temperature of incubation, medium composition, and pH." | ( Influence of in vitro susceptibility testing conditions on the anti-candidal activity of LY121019. Gerarden, T; Pfaller, MA; Wenzel, RP; Yu, M, 1988) | 0.27 |
| " With 15 mg of cilofungin per kg twice a day for 10 days, a survival rate of 43 to 50% was observed in both normal and granulocytopenic mice compared with 56 and 60%, respectively, when this dosage was continued for 30 days." | ( Comparative efficacies of cilofungin (Ly121019) and amphotericin B against disseminated Candida albicans infection in normal and granulocytopenic mice. Bodey, GP; Kalvakuntla, L; Khardori, N; Nguyen, H; Rosenbaum, B; Stephens, LC, 1993) | 0.94 |
| " Dosing is once daily and drug interactions are few." | ( Echinocandin antifungal drugs. Denning, DW, 2003) | 0.32 |
| Role | Description |
|---|---|
| antiinfective agent | A substance used in the prophylaxis or therapy of infectious diseases. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| echinocandin | Any one of a family of large lipopeptides that are inhibitors of the enzyme 1,3-beta-glucan synthase, thus damaging fungal cell walls. Echinocandins are fungicidal against most Candida spp and fungistatic against Aspergillus spp. |
| antibiotic antifungal drug | Any antibiotic antifungal agent used to treat fungal infections in humans or animals. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Pathway | Proteins | Compounds |
|---|---|---|
| echinocandin B degradation | 0 | 6 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 32 (40.00) | 18.7374 |
| 1990's | 43 (53.75) | 18.2507 |
| 2000's | 4 (5.00) | 29.6817 |
| 2010's | 1 (1.25) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (17.36) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (1.20%) | 5.53% |
| Reviews | 4 (4.82%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 78 (93.98%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||